This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SPIDIA4P | |
|---|---|
| Name | SPIDIA4P |
| Type | Research project |
| Field | Molecular diagnostics; Biobanking |
| Established | 2019 |
| Location | Europe |
| Funding | European Commission; Horizon 2020 |
SPIDIA4P is a European collaborative project focused on pre-analytical workflows for in vitro diagnostics and precision medicine, aiming to develop evidence-based standards for biospecimen handling. It builds on prior initiatives in molecular diagnostics, harmonization, and quality assurance to improve diagnostic reproducibility across clinical laboratories, biobanks, regulatory agencies, and industry partners.
SPIDIA4P synthesizes work from projects and institutions such as European Commission, European Medicines Agency, European Centre for Disease Prevention and Control, World Health Organization, European Research Council, European Molecular Biology Laboratory, National Cancer Institute (United States), International Organization for Standardization, International Society for Biological and Environmental Repositories, European Biobanking and Biomolecular Resources Research Infrastructure, Agence Nationale de la Recherche, German Cancer Research Center, University of Oxford, Karolinska Institutet, University of Cambridge, University of Basel, Technische Universität München, Friedrich-Alexander-Universität Erlangen-Nürnberg, Leiden University Medical Center, Consortium of European Biobanks, European Federation of Pharmaceutical Industries and Associations, European Association of Hospital Pharmacists, Food and Drug Administration, National Institute for Health and Care Excellence, EORTC, European Society for Medical Oncology, European Tissue Bank Network, European Clinical Research Infrastructure Network, Belgian Nuclear Research Centre, Royal Society, Deutsche Forschungsgemeinschaft, Wellcome Trust, Institut Pasteur, Centro Nacional de Investigaciones Oncológicas, Karolinska University Hospital, Mayo Clinic, Johns Hopkins Hospital, CERN.
SPIDIA4P aims to harmonize pre-analytical processes for biospecimens used in molecular assays by producing technical specifications, validation studies, and training materials for stakeholders such as clinical laboratories, biobanks, in vitro diagnostic manufacturers, regulatory authorities, pharmaceutical companies, academic hospitals, pathology departments, clinical trial networks, biotech startups, public health institutes, patient advocacy groups, health technology assessment agencies, and professional societies including European Society of Pathology and American Society for Clinical Pathology. The project scope includes blood, plasma, serum, tissue, and nucleic acid workflows intended to support next-generation sequencing, digital PCR, mass spectrometry, immunohistochemistry, liquid biopsy applications, and companion diagnostic development aligned with IVD Regulation (EU), Clinical Laboratory Improvement Amendments, and international guidance from Clinical and Laboratory Standards Institute.
SPIDIA4P uses inter-laboratory ring trials, blind proficiency testing, and multicenter validation involving partners such as European Molecular Genetics Quality Network, UK Accreditation Service, German Accreditation Body, NATO Science for Peace, European Standards Committee, European Committee for Standardization, Organisation for Economic Co-operation and Development, International Laboratory Accreditation Cooperation, European Pharmacopoeia Commission, European Society for Translational Medicine, Biobanking and Biomolecular Resources Research Infrastructure IT platform, and major clinical centers. Protocols were developed through systematic evidence review, experimental comparison of pre-analytical variables, and statistical analysis guided by experts from Stanford University School of Medicine, Harvard Medical School, Imperial College London, ETH Zurich, and University of Copenhagen. Outputs include draft technical specifications suitable for adoption as ISO standards and validation packages for Notified Bodies and regulatory submissions.
Key findings emphasize the impact of collection device choice, storage temperature, transport time, centrifugation parameters, freeze–thaw cycles, and extraction methods on nucleic acid integrity and protein biomarkers measured by whole-genome sequencing, targeted sequencing panels, RNA-Seq, microarray assays, enzyme-linked immunosorbent assay, and mass spectrometry-based proteomics. Recommendations prioritize standardized collection tubes, defined temperature-controlled logistics consistent with practices at European Centre for Disease Prevention and Control and World Health Organization guidance, validated SOPs for processing within specified time windows, and certified reference materials to support calibration with standards from Joint Research Centre. The project produced validation matrices and decision trees to guide laboratories adopting companion diagnostics and companion therapies in oncology, infectious disease, and rare disease contexts endorsed by professional societies like European Society for Medical Oncology.
The consortium includes academic research centers, clinical laboratories, biobanks, industrial partners including diagnostic manufacturers, and regulatory and standards bodies. Notable participating institutions and stakeholders include European Commission Horizon 2020, European Molecular Biology Laboratory, Institut Pasteur, Karolinska Institutet, University of Oxford, German Cancer Research Center, Leiden University Medical Center, Mayo Clinic, Johns Hopkins University, European Medicines Agency, Clinical and Laboratory Standards Institute, International Organization for Standardization, European Society for Pathology, European Biobanking and Biomolecular Resources Research Infrastructure, Wellcome Trust, Deutsche Forschungsgemeinschaft, NHS England, Agence Nationale de la Recherche, Italian National Institute of Health, and multiple small and medium enterprises in the diagnostics sector.
Implementation pathways emphasize integration into laboratory accreditation, clinical trial protocols, and regulatory submissions, influencing biomarker reliability in precision oncology, infectious disease diagnostics, and personalized therapeutics developed by companies like AstraZeneca, Roche, Pfizer, Novartis, GlaxoSmithKline, Sanofi, Bristol-Myers Squibb, Merck & Co., Bayer, AbbVie, and Johnson & Johnson. Improved pre-analytical standardization reduces assay variability, supports reproducible biomarker-driven clinical trials coordinated by networks such as EORTC and European Clinical Trials Alliance, and informs health technology assessment by agencies like NICE and Haute Autorité de Santé.
Critiques concern generalizability across diverse healthcare settings including low-resource environments represented by stakeholders like World Bank initiatives and variability in adoption by decentralized clinical systems such as those in the United States and India. Limitations include the focus on specific specimen types and assays, dependency on consortium funding mechanisms like Horizon 2020, and challenges translating technical specifications into binding ISO standards and regulatory requirements enforced by agencies including European Medicines Agency and Food and Drug Administration.
Category:Biobanking Category:Precision medicine